341 related articles for article (PubMed ID: 26259780)
1. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
2. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Wen YH; Ho A; Patil S; Akram M; Catalano J; Eaton A; Norton L; Benezra R; Brogi E
Breast Cancer Res Treat; 2012 Aug; 135(1):93-102. PubMed ID: 22538771
[TBL] [Abstract][Full Text] [Related]
3. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
4. Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Kim MC; Choi JE; Lee SJ; Bae YK
Ann Surg Oncol; 2016 Oct; 23(11):3524-3530. PubMed ID: 27278204
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
6. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
8. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
[TBL] [Abstract][Full Text] [Related]
9. p53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer.
Wang X; El-Halaby AA; Zhang H; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
Hum Pathol; 2017 Oct; 68():22-25. PubMed ID: 28438622
[TBL] [Abstract][Full Text] [Related]
10. miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.
Crippa E; Lusa L; De Cecco L; Marchesi E; Calin GA; Radice P; Manoukian S; Peissel B; Daidone MG; Gariboldi M; Pierotti MA
PLoS One; 2014; 9(1):e87039. PubMed ID: 24475217
[TBL] [Abstract][Full Text] [Related]
11. Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Lee HB; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
Breast Cancer Res Treat; 2019 May; 175(1):117-127. PubMed ID: 30671767
[TBL] [Abstract][Full Text] [Related]
12. p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.
Coates PJ; Nenutil R; Holcakova J; Nekulova M; Podhorec J; Svoboda M; Vojtesek B
Virchows Arch; 2018 Mar; 472(3):351-359. PubMed ID: 29484502
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
[TBL] [Abstract][Full Text] [Related]
14. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
15. Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer.
Roldán G; Delgado L; Musé IM
Cancer Biol Ther; 2006 May; 5(5):505-10. PubMed ID: 16582598
[TBL] [Abstract][Full Text] [Related]
16. A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.
Buckley NE; Haddock P; De Matos Simoes R; Parkes E; Irwin G; Emmert-Streib F; McQuaid S; Kennedy R; Mullan P
Oncotarget; 2016 Apr; 7(15):19884-96. PubMed ID: 26943587
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations in sporadic triple negative breast cancer.
Pop LA; Cojocneanu-Petric RM; Pileczki V; Morar-Bolba G; Irimie A; Lazar V; Lombardo C; Paradiso A; Berindan-Neagoe I
Breast; 2018 Apr; 38():30-38. PubMed ID: 29202330
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer.
Dimas-González J; Maldonado-Lagunas V; Díaz-Chávez J; López-Arellano ME; Muñoz-Camacho J; Terán-Porcayo MA; Lagunas-Martínez A
Oncol Rep; 2017 May; 37(5):3026-3036. PubMed ID: 28393224
[TBL] [Abstract][Full Text] [Related]
20. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
Deb S; Jene N; ; Fox SB
BMC Cancer; 2012 Nov; 12():510. PubMed ID: 23146383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
